Home Contact Us ABOUT HALOZYME NEWSROOM TECHNOLOGY PRODUCTS & PIPELINE INVESTORS CAREERS INVESTIGATORS NEWS HEADLINES 08/24/15 Halozyme Appoints Michael J. LaBarre As Chief Scientific Officer 08/10/15 Halozyme Reports Second Quarter 2015 Financial Results 08/06/15 UCSF To Study Halozyme PEGPH20 In Pancreatic Cancer Patients Who Are Candidates For Potentially Curative Surgery More news WHO WE ARE Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, our investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen, Baxalta and AbbVie for its drug delivery platform, ENHANZE™, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego, CA. Website Design: Hane Chow Inc. © 2011, 2012 Halozyme, Inc. All rights reserved. All trademarks belong to their respective owners. Terms of Use / Privacy Policy Powered By Q4 Web Systems 4.1.1.49